Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Are Monash IVF Shares A Blockbuster Buy?

The Monash IVF Group Ltd (ASX: MVF) share price jumped nearly 5% yesterday after announcing the acquisition of another fertility clinic.

Monash IVF has been one of the strongest performers on the ASX over the past two months, rising nearly 30%. The strong momentum continued yesterday as the company announced they had acquired Fertility Solutions, a Queensland based provider of fertility services.

Who Are Monash IVF?

Monash IVF Group is a leading provider of assisted reproductive services. Basically, they assist couples who wish to have children but for one reason or another have difficulty in conceiving a child naturally. Technology has come a long way since the first IVF pregnancy back in 1973 and Monash IVF is at the forefront of these developments.

The Acquisition

Monash IVF has agreed to acquire Fertility Solutions for a purchase price of $2.1 million with the possibility of additional earn-out payments over a four-year period until June 30, 2023. Management said they expect to complete the transaction during the first quarter of the financial year subject to all conditions being met.

Fertility Solutions was established in 2007 and have two clinics operating out of Bundaberg and Buderim on the Sunshine Coast. As a result of the purchase, Monash IVF will gain access to a further six fertility specialists who will be integrated into the Monash IVF clinician network.

“Fertility Solutions is a high quality business providing an excellent geographic and cultural fit with Monash IVF,” Monash IVF CEO Michael Knaap said.

“Monash IVF currently has no presence in the attractive markets of the Sunshine Coast and Bundaberg, and the acquisition is consistent with our strategic priority of establishing a more balanced business portfolio across Australia.”

Given Monash IVF has a market capitalisation in excess of $300 million, the acquisition of Fertility Solutions is only very minor with the purchase price representing less than 1% of the company’s value. Viewed in this context the acquisition hardly seems noteworthy. However, I believe investors view it as a more important purchase from a strategic perspective.

In the current low-interest rate environment, investors are being chased out of cash and are desperately searching for places to invest their capital with an eye to growth. The fact that management stated that they expect the acquisition to be profit/earnings accreditive right from the beginning is likely to have caught the eyes and ears of investors.

Time To Monash IVF?

The Monash IVF share price has some strong positive momentum right now but I will be waiting to see the release of their FY19 financial statements and surrounding management commentary before considering buying any shares.

[ls_content_block id=”14947″ para=”paragraphs”]

Disclosure: At the time of publishing, Luke has no financial interest in any companies mentioned.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Skip to content